eMJA: Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia

To the Editor: We question the conclusions drawn by Canfell and colleagues1 from their analysis of trends in hormone replacement therapy (HRT) prevalence and breast cancer incidence for Australian women aged 50 years or older. Their ecological analysis lacks individual-level information on HRT use and information on tumour oestrogen receptor (ER) status, and captures only 2 years following the decline in HRT prevalence. This is an inadequate design within which to judge issues of causality; it is at best an hypothesis-generating exercise.2

NB: If you are registered with the eMJA, your username is the email address you have provided.
If you don't have a login, click here for subscription options. You will be prompted to create an account upon purchase.

AMA members can login using their AMA username and password.
If you don't know your AMA password, please contact the AMA on 02 6270 5400 or membership@ama.com.au, or try to retrieve your password at this address.

The Medical Journal of Australia eMJA

Username:
Password:

Password forgotten? Click here What is my username?